Protective Effect of Urolithin a on Cisplatin-induced Nephrotoxicity in Mice Via Modulation of Inflammation and Oxidative Stress
Overview
Toxicology
Authors
Affiliations
Limitation of widely used anti-cancer agent cisplatin for a patient is nephrotoxicity. Nephrotoxicity is presentable in mice by injecting cisplatin at 25 mg/kg with 3 days endpoint. We used the same model to understand the protective role of urolithin A. Cisplatin-induced renal damages measured by histological damage in proximal tubular cells and by the increase in serum neutrophil gelatinase-associated lipocalin (NGAL), blood urea nitrogen (BUN), creatinine and urinary Kidney Injury Molecule-1 (KIM-1). Urolithin A pretreatment reduced all the above renal damage parameters in a significant way. Urolithin A attenuated cisplatin-induced pro-inflammatory cytokine/chemokine tumor necrosis factor α (TNFα), interleukin 23 (IL-23), interleukin 18 (IL-18) and macrophage inflammatory protein 2 (MIP2). Cisplatin-induced CD11b positive macrophages in kidneys reduced by urolithin A. Urolithin A also attenuated cisplatin-induced renal oxidative/nitrative stress, which was measured by lipid peroxidation(4-hydroxy-2-nonenal or 4-HNE protein adducts) and protein nitration. Urolithin A cisplatin-induced kidney injury in mice through the down regulation of inflammatory cytokines/chemokine, immune cells, and oxidative/nitrative stress thus improving cisplatin-induced proximal tubular cell death.
Alfei S, Zuccari G Int J Mol Sci. 2025; 26(2).
PMID: 39859559 PMC: 11766176. DOI: 10.3390/ijms26020844.
Azmat F, Safdar M, Ahmad H, Khan M, Abid J, Naseer M Food Sci Nutr. 2024; 12(2):661-674.
PMID: 38370077 PMC: 10867480. DOI: 10.1002/fsn3.3777.
Alrashdi B, Mohamed R, Mohamed A, Samoul F, Mohamed M, Moussa M Biosci Rep. 2023; 43(11).
PMID: 37902021 PMC: 10643052. DOI: 10.1042/BSR20231130.
Revankar A, Bagewadi Z, Shaikh I, Mannasaheb B, Ghoneim M, Khan A Saudi J Biol Sci. 2023; 30(11):103804.
PMID: 37727526 PMC: 10505678. DOI: 10.1016/j.sjbs.2023.103804.
Urolithin A in Health and Diseases: Prospects for Parkinson's Disease Management.
Wojciechowska O, Kujawska M Antioxidants (Basel). 2023; 12(7).
PMID: 37508017 PMC: 10376282. DOI: 10.3390/antiox12071479.